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Abstract
The case of a 39-year-old man with slowly growing mass in the superior part of left parotid region is described. 
Patient presented neurological symptoms including hypomobility of lower left eyelid and inability of complete 
closure of left side eyelids resulting in conjunctivitis and hyperlacrimation. Routine physical examination sup-
ported by image and laboratory tests was performed. Pathomorphological results of hematoxylin and eosin 
staining as well immunohistochemical examination in view of clinical presentation pointed to diagnosis of high 
grade salivary duct carcinoma. Rare incidence, histological view similar to breast cancer and body localization 
are sufficient reasons for further analyses and descriptions of this type of lesions. (Folia Histochemica et Cyto-
biologica 2015, Vol. 53, No. 4, 342–345)
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Introduction
The salivary duct carcinoma (SDC) is an uncommon 
aggressive malignancy localized in the head and neck 
region most commonly involving parotid gland. It 
was described for the first time by Kleinsasser et al. 
in 1968 and due to rather rare incidence insufficient 
descriptions of SDC can be found in literature [1, 2]. 
Clinical symptoms may not be present, while if they 
occur, mostly often pain, swelling and paresis are 
reported. Histopathologically it resembles high grade 
ductal breast carcinoma structure with frequently 
observed perineural spread, lymphovascular invasion 
with intraductal emboli. Surgery is a common treat-
ment of choice followed by adjuvant radiotherapy, 
supplemented by chemotherapy in advanced cases. 
Prognosis is rather poor and is strongly associated 
with clinical course [1]. Due to many similarities with 
breast cancer as well still incoherent diagnostic and 
therapeutic procedures we present our case study.
Case report
The 39-year-old man complaining of decreased mo-
bility of lower left eyelid and painless swelling of the 
left preauricular area was admitted to the surgical 
department. Within the last three months, the patient 
was diagnosed and treated for sialoadenitis whereas 
present symptoms occurred within three weeks. The 
physical examination revealed left eye lagophtalmus 
(inability of complete closure of eyelids) and lower 
eyelid hypomobility resulting in conjunctivitis and 
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hyperlacrimation. The eye movement inability, nei-
ther diplopia were not present. The left parotid gland 
fulfilled the parotideomasseterical region of the same 
side in a form of solid, firm mass. Cervical lymphade-
nopathy was absent. Problems with mouth opening, 
mastication and local tenderness as well as intraoral 
pathology were not observed. Overall patient’s condi-
tion was good, chronic diseases and pharmacotherapy 
were not reported, family medical history (including 
breast cancer) was irrelevant. Magnetic resonance im-
age examination revealed tumor of lobular structure 
(22 × 21 × 27 mm) in dorsocranial area of the left 
parotid glad adjacent to the left mandibular condyle 
and the ear canal. Margins were clearly defined, 
without any infiltration and centrally located necrosis. 
The unaffected salivary gland neighboring the tumor 
revealed slightly higher density in computed tomogra-
phy (CT) scans whereas in the central part of parotid 
gland showed incorporated hypodensity area (diame-
ter 6 mm) what finally was diagnosed by radiologists 
as an active or metastatic lymph node. Other lymph 
nodes in CT examination didn’t reveal any features of 
pathology. The chest X-ray image was normal. Radical 
parotidectomy was selected as a treatment of choice 
due to signs and symptoms of malignant process (par-
tial facial nerve paralysis, tumorous mass with central 
necrosis and suspicious lymph node metastasis). The 
location of the tumor enabled to save buccal, man-
dibular and cervical branches of the left facial nerve, 
whereas temporal and zygomatic were resected with 
neoplastically changed masses. Specimen consisted of 
lipomesenchymal masses with a visible structures of 
parotid salivary gland and several yellow-white solid 
bearings from 0.3–1.3 cm in diameter. The dissected 
material was sent for histopathological examination 
while soft tissue defect was closed locally. 
Routine hematoxylin and eosin (H & E) staining 
performed on paraffin embedded material revealed 
lipomatous salivary gland structure infiltrated by high 
grade carcinoma with an extensive perineural spread-
ing and invasion into lymphatic vessels. The presence 
of an intraductal component with comedonecrosis 
(Figure 1) was observed in approximately 10% of 
tumor mass. A desmoplastic reaction was present in 
the vicinity of the neoplasm. Out of the three iden-
tified/resected lymph nodes, two were metastatic. 
The neoplastically changed tissue was composed of 
a population of polygonal elements with a fine glandular 
and/or a homogenous eosinophilic cytoplasm. The 
nuclei were mostly anisomorphic within prominent 
nucleoli (focally multiplied). A rich mitotic activity 
(including atypical mitoses) was evident (10–20 per 
10 high power fields). For set up a final diagnosis in view 
of above described results the panel of 11 markers 
was used. All procedures were conducted according 
to running immunohistochemical protocols. Direct 
monoclonal antibodies against Ki-67 (clone MIB-1, 
1:100), cytokeratin (CK, clone AE1/AE3, 1:100), CK 7 
(clone OV-TL12/30, 1:100), carcinoembrionic antigen 
(CEA, clone II-7, 1:50), estrogen receptor (ER, clone 
1D5, 1:50), progesterone receptor (PR, clone PgR636, 
1:200), prostatic specific antigen (PSA, clone ER-
PR8, 1:50), p63 (clone 4A4, 1:50), calponin-1 (clone 
EP789Y, 1:100) and polyclonal against S100 protein 
(1:600) and HER-2 (1:400) were used. All reagents 
and antibodies except anti-p63 and anti-calponin 
(Zytomed, Berlin, Germany) were obtained from 
DakoCytomation, Glostrup, Denmark. The prolifer-
ation activity index measured by Ki-67 expression was 
50%. The evident positive reaction was observed for 
CK, CK 7 and CEA while for HER-2 it was interme-
diate. No expression of ER, PR, PSA, p63, s100 and 
calponin-1 was observed. Final diagnosis was salivary 
duct carcinoma with pathological advancement clas-
sification pT2, pN2, pMx and grade of histological 
malignancy G3. 
During the postoperative recovery period the 
patient underwent adjuvant four field simultaneous 
integrated boost radiotherapy with a modulated 
intensity of the beam. The total dose was counted as 
54–60–66 Gy in 30 fractions. A complete left facial 
nerve paralysis with good response to the rehabilita-
tion procedures was observed. During 12 months of 
follow-up period muscles innervated by unresected 
branches of the left facial nerve restored their func-
tion. A permanent left eye lagophtalmos causes 
a reasonable discomfort for the patient. 
State of the art 
SDC is an uncommon aggressive malignancy localized 
in the head and neck region. Up to 80% of cases 
occurs in parotid, in which they are mostly located in 
lateral (superficial) lobe. It comprises approx. 15–23% 
of tumors located in parotid. Annual incidence of 
malignant tumors varies from 0.4 to 2.6 cases/100,000 
population per year with visible geographic variations 
in frequency of tumor type. It is observed 4 times of-
ten in men occurring after fifth decade of life and it 
represents approximately 9% of all salivary malignan - 
cies [1]. It has been suggested that approximately 
25% of SDC arose from pre-existing pleomorphic adeno- 
ma [3]. Development of salivary duct tumors was as-
sessed in view of viral infections (mostly Epstein-Barr 
virus, cytomegalovirus and SV40) but results are 
equivocal [1, 4]. Whereas involvement of ionizing 
radiation and increased expression of hormone 
receptors (ER, PR and AR; androgen receptor) in 
344 Jiri Borovec et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2015
10.5603/FHC.a2015.0031
www.fhc.viamedica.pl
Figure 1. Microphotographs of routine hematoxylin and eosin staining (A–E) and immunohistochemical reactions (F–H) 
showing features of salivary duct carcinoma (SDC). A, B. Intraductal component of SDC with comedonecrosis (×40 and  
×100, respectively); C. Infiltrating growth of SDC (×100); D. Perineural invasion of SDC (×100); E. High mitotic activity, 
cancer nest (×400). Immunohistochemical nuclear expression of Ki-67 (F; ×100) and cytoplasmic expression of carcino-
embrionic antigen (G; ×40) and HER-2 (H; ×200)
A B
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salivary tissue is strongly evidenced [5, 6]. No associ-
ation between tobacco use and alcohol consumption 
was found. Symptoms vary from massive edema, 
pain, inflammation, mastication and vocalization 
problems in aggressive forms of SDC, to even asymp-
tomatic in slowly growing entities. Normally SDC is 
characterized by an invasive local growth with early 
distant metastases. The radiographic examination 
gives unspecific results and should be rather used to 
verify localization during diagnostics instead of setting 
a diagnosis. Ultrasound, CT and MRI examinations give 
much more precise results revealing typical features 
of SDC [7]. The final diagnosis is based on the regular 
histopathological examination, because fine needle 
aspiration biopsy, which sometimes is performed may 
not give convincing results. Instead of routine H & E 
stained sections analyzed by pathomorphologist 
who is searching for typical features i.e. tumor nests, 
perineural spread, intraductal emboli, additional 
immunohistochemical reactions may be performed. 
Due to morphologic and molecular similarity to breast 
cancer, histopathological as well molecular profiling 
should be conducted to provide effective diagnostics 
and treatment. Consequently, Ki-67, ER, PR, HER-2 
markers should be tested, with additional set of AR, 
CK, p53 and epithelial growth factor receptor, as 
proposed by other researchers [4, 8, 9]. The classi-
fication of salivary gland tumors is rapidly evolving 
with description of new entities, such as mammary 
analogue secretory carcinoma (MASC), whereas 
entities, such as salivary duct carcinoma, are being 
increasingly recognized with improved understanding 
of their molecular characteristics [10]. Genetic events 
which might occur in SDC, i.e. loss of heterozygosity 
associated with expression of epithelial growth factor 
receptor family proteins (e.g. HER-2) and p53 genes 
which result in the overexpression of the protein, what 
potentially may be used for therapy [11, 12]. The first 
therapeutic step comprises the radical surgery inter-
vention with suspicious lymph node dissection, fol-
lowed by radiotherapy. The chemotherapy is reserved 
for metastatic stages of SDC. The results of a recent 
studies have suggested that HER-2 overexpression is 
associated with a poor prognosis. Therefore, HER-2 
status should be evaluated at least in the presence 
of advanced SDC, and targeted therapy should be 
considered in the adjuvant setting [13]. During regu-
lar course of the disease as well after recommended 
treatment whole or partial facial nerve paralysis is 
very often observed, even up to 60% of cases [1, 5, 7]. 
Prognosis is relatively poor and most strongly corre-
lates with clinical stage. Despite aggressive surgery 
and additional radiotherapy approximately one 
third of patients develop local recurrence and nearly 
50% distant metastases. 65% of patients dies of SDC 
usually within 4 years after diagnosis [1, 14]. Further 
analyses of this neoplastic entity may be useful in 
diagnostic process as well in therapeutic usage. 
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